Company news

Kymera Therapeutics, Inc. (NASDAQ:KYMR) news

Kymera Therapeutics, Inc. news releases on 6ix. Latest, Sep 1, 2026: Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6…

Kymera Therapeutics, Inc. (NASDAQ:KYMR) news

Press releases & updates

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera International Appoints Willson Ropp as Chief Executive Officer

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

Kymera Therapeutics Announces Proposed Public Offering

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update